08:30 AM EDT, 10/13/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that its investigational cancer antigen therapy, mRNA-4359, in combination with pembrolizumab, has shown "promising" results in its phase 1/2 trial in certain Melanoma patients.

The company said the combination therapy achieved a 24% objective response rate and a 60% disease control rate.

Among a subgroup of patients whose tumors expressed PD-L1, the company said the response rate was 67%.

The treatment also induced peripheral antigen-specific T cell responses and the novel T cell receptor clones, the company said.

Moderna ( MRNA ) also said the median duration of response has not yet been reached, suggesting potential durability.

The combination was well tolerated, with no new immune-related safety issues reported.

Moderna ( MRNA ) said it continues to study mRNA-4359 in the phase 2 portion of the ongoing phase 1/2 trial both as a standalone therapy and in combination with pembrolizumab in patients with advanced melanoma and non-small cell lung cancer.

Shares of the company were up 1% in recent Monday premarket activity.